Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.

Christie M Ballantyne1

  • 1Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, USA. cmb@bcm.tmc.edu

The American Journal of Cardiology
|November 18, 2005
PubMed
Summary

Statin therapy significantly reduces coronary artery disease (CAD) events, but patients still face risks. New guidelines recommend lower low-density lipoprotein (LDL) cholesterol targets, necessitating advanced treatment strategies for optimal cardiovascular risk reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

The lancet. Diabetes & endocrinology·2017
Same author

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Atherosclerosis·2017
Same author

Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study.

Nutrition (Burbank, Los Angeles County, Calif.)·2017
Same author

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

Journal of clinical lipidology·2017
Same author

The Upregulation of Integrin α<sub>D</sub>β<sub>2</sub> (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.

Nature reviews. Cardiology·2017

Area of Science:

  • Cardiology
  • Lipid Metabolism
  • Preventive Cardiology

Background:

  • Statin therapy consistently reduces coronary artery disease (CAD) events.
  • Residual CAD risk persists in statin-treated patients despite significant low-density lipoprotein (LDL) cholesterol reduction.
  • Updated guidelines advocate for more aggressive LDL cholesterol targets in high-risk populations.

Purpose of the Study:

  • To address the need for enhanced treatment strategies to achieve lower LDL cholesterol goals.
  • To explore the potential of targeting multiple lipid pathways for greater LDL cholesterol reduction and improved lipid parameters.
  • To highlight the necessity for clinical trials evaluating optimal cardiovascular risk reduction strategies.

Main Methods:

  • Review of recent clinical trial evidence supporting lower LDL cholesterol targets.

Related Experiment Videos

  • Analysis of updated treatment guidelines for cardiovascular risk management.
  • Discussion of multi-pathway lipid-targeting strategies.

    • Main Results:

    • Lower LDL cholesterol targets are supported by recent clinical evidence.
    • Updated guidelines include optional, more aggressive LDL cholesterol goals for specific patient groups.
    • Targeting multiple lipid pathways offers potential for enhanced LDL cholesterol reduction and improved lipid profiles.

    Conclusions:

    • Achieving lower LDL cholesterol goals requires enhanced treatment strategies beyond current statin therapy.
    • Multi-pathway lipid targeting may offer superior reductions in LDL cholesterol and other lipid parameters.
    • Further clinical trials are essential to identify optimal treatment strategies for cardiovascular risk reduction.